**Drug Law Committee Mission**

The purpose of the Drug Law Committee is, in part, to keep the pharmaceutical industry and legal practitioners up to date and provide practical advice concerning issues that are of interest to the industry. Such issues involve the U.S. Food and Drug Administration’s regulation of drug products and drug substances, pending legislation and implementation of legislation related to the pharmaceutical industry, and interactions with the Food and Drug Administration, other agencies within Health and Human Services, the Federal Trade Commission, and state agencies. The Committee will consider relevant regulatory and legislative developments for comment or rulemaking initiation, and will follow the recent trends involving off-label promotion and advertising, generic drug labeling and product liability, risk evaluation and mitigation systems (REMS), federal and state antitrust enforcement, opioids and abuse deterrent products, developments concerning generic drug approvals and Hatch-Waxman litigation, and prescription to OTC switches, among others.

The Committee will also seek to engage members in programming and activities to contribute to the development of sound laws, policies and regulations concerning the pharmaceutical industry. These activities will provide members with opportunities to network with colleagues on the committee and with relevant external organizations and individuals.